Stylus Medicine Emerges from Stealth with $85M Series A to Advance In Vivo CAR-T Therapies

May 13, 2025 08:22 CST Updated 08:22

Stylus Medicine

Gene Drug Developer

RA Capital

Life Sciences Venture Capital Firms

Eli Lilly

Global Pharmaceutical R&D and Production Company

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

Khosla Ventures

Venture Capital Firms

Myeloma Investment Fund

Multiple Myeloma Investment Institutions

Tachyon Ventures

A Venture Capital Firm Focused on Early-Stage Life Sciences

Chugai Pharmaceutical

Developer and Manufacturer of Anti-Cancer Drugs

May 12, Boston – Stylus Medicine, a biotechnology company developing in vivo gene therapies to unlock treatments, emerged from stealth mode with an $85 million Series A financing.The Stylus Medicine platform is powered by engineered recombinases that encode therapeutic agents with high precision. Investors include RA Capital, Eli Lilly and Company, Johnson & Johnson, Chugai Pharmaceutical Co., Ltd., Khosla Ventures, Myeloma Investment Fund, and Tachyon Ventures.Stylus MedicineProviding genome engineering and chromatin regulation technologies to develop enzyme and drug delivery methods for targeted gene editing in vivo, capable of inserting gene sequences of any length into the human genome to develop permanent treatments for patients.

Stylus MeDicine's recombinase is designed to recognize safe sites in the human genome and introduce therapeutic payloads with high specificity and integrity. The features of this approach include:Introduce therapeutic payloads for specific sequences;Reproducible, predictable, and characteristic insertion;Full-length fidelity, no exposed twisted pair breakage;Large, complex, multi-gene therapeutic payload capacity.

The initial focus was on creating an in vivo CAR-T therapy. This method enables precise and durable CAR-T generation within the body. These CAR-T treatments utilize cell-targeting lipid nanoparticles (LNPs) to deliver therapeutic payloads directly to immune cells within the body. This approach has the potential to transform patient treatment, enhance accessibility for patients, and redefine the possibilities of medicine.Potential indications for in vivo CAR-T therapy include tumors, autoimmune diseases, and genetic disorders.

Emile Nuwaysir is the Chairman and Chief Executive Officer of Stylus Medicine, Inc.Previously, Emile served as the Chief Executive Officer and Chairman of BlueRock Therapeutics, a subsidiary independently operated under Bayer Pharmaceuticals. From the onset of his role as CEO, Emile helped establish a platform company at the intersection of cellular and genetic medicine, developed a series of first-class therapeutic programs, and managed the company’s acquisition and operations by Bayer. Emile is also the former CEO of Ensoma and the former Chairman of the Alliance for Regenerative Medicine, an international advocacy organization comprising over 400 member companies dedicated to advancing cell and gene therapies.

Jason Fontenot is the Chief Scientific Officer of Stylus Medicine. Before joining Stylus, Jason served as the Chief Strategy Officer at Sangamo Therapeutics. Prior to Sangamo, he was the Chief Strategy Officer at Immusoft and had previously held the position of Head of Exploratory Research at Juno Therapeutics. Before his time at Juno, Jason worked as the Leader of the Immunology Research Group at Biogen.

Patrick Hsu: "La edición genética ya cura pacientes en fase clínica, y ...

ACo-founder of RC Research Institute,University of California, BerkeleyProfessor of BioengineeringDr. Patrick Hsu is the founder of the company.Patrick HsuA Pioneer in CRISPR Gene EditingZhang FengThe first graduate student of the professor. Other scientific founders include Stanford.UniversityAmi S. BhattProfessor、Michael C. BassikProfessorAndProfessor Lacramioara Bintu.

On June 26, 2024, Arc InstitutePatrick Hsu et al. inNature The journal published two research papers concurrently, describing a bridge-inspired ...RNA（Bridge RNA）Characteristics of guided recombinases, which can insert, invert, or delete long fragments at specific genomic lociDNASequence, thereby enabling these recombinases to be reprogrammed for new genomic editing capabilities.

Follow the official account below to see the world!